ABSTRACT
Purpose: Data showed seroconversion after different SARS-CoV-2 vaccination platforms might yield diminished response in transplant recipients. However, it is unknown whether different vaccination platforms could offer a specific grade of protection against SARS-CoV-2. Method(s): we prospectively studied adult kidney & liver recipients who received who had no previous COVID-19 infection, and received either ChAdOx1 or BNT- 162b2 vaccines between January 2021 to September 2021, with an assessment of IgM/IgG spike (S) antibodies. Result(s): Our cohort is composed of kidney (n=235) or liver (n=217) patients, who have received either ChAdOx1 (N=157) or BNT-162b2 (n=295). The response was higher with mRNA vaccine. Unresponsiveness is found to be mainly linked to diabetes and older age. Side effects were similar to those reported in clinical trials. Conclusion(s): mRNA vaccines might elicit a higher humoral immunity response as compared with ChAdOx1 in immunosuppressed transplant patients.